AMRX Q1 2020 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$499M+11.7% YoY

Gross Profit

$183M36.8% margin

Operating Income

$58M11.6% margin

Net Income

$115M23.1% margin

EPS (Diluted)

$0.78

QoQ Revenue Growth

+25.5%

Cash Flow

Operating Cash Flow

$49M

Free Cash Flow

$41M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$4.0B

Stockholders' Equity

$318M

Cash & Equivalents

$405M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$499M	$446M	+11.7%
Gross Profit	$183M	$83M	+120.9%
Operating Income	$58M	-$94M	+161.2%
Net Income	$115M	-$48M	+340.3%

Revenue Segments

Specialty Segment

$88M60%

Av K A R E Segment

$58M39%

Generics Segment

$985,0001%